ReviewBiotechnology advances
Streptomycetes: Surrogate hosts for the genetic manipulation of biosynthetic gene clusters and production of natural products.
Review in Biotechnology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 106 citations in OpenAlex.
- Review
- A Simple and Versatile Cell-Free Expression Method for Producing Secondary Metabolites.ACS synthetic biology · 2026Article
- iCASRED, a scarless DNA editing tool inSynthetic and systems biotechnology · 2025Article
- A highly efficient heterologous expression platform to facilitate the production of microbial natural products in Streptomyces.Microbial cell factories · 2025Article
- Positive regulation of a LuxR family protein, MilO, in mildiomycin biosynthesis.Applied and environmental microbiology · 2025Article
- Metabolic engineering approaches for the biosynthesis of antibiotics.Microbial cell factories · 2025Review
- Conjugation Mediates Large-Scale Chromosomal Transfer in Streptomyces Driving Diversification of Antibiotic Biosynthetic Gene Clusters.Molecular biology and evolution · 2024Article
- Discovery, characterization, and engineering of an advantageous Streptomyces host for heterologous expression of natural product biosynthetic gene clusters.Microbial cell factories · 2024Article
- Article
- MCF2Chem: A manually curated knowledge base of biosynthetic compound production.Biotechnology for biofuels and bioproducts · 2023Article
- Identification and characterization of a strong constitutive promoter stnYp for activating biosynthetic genes and producing natural products in streptomyces.Microbial cell factories · 2023Article
- Genomics-Guided Efficient Identification of 2,5-Diketopiperazine Derivatives from Actinobacteria.Chembiochem : a European journal of chemical biology · 2023Article
- Development of a native-locus dual reporter system for the efficient screening of the hyper-production of natural products inFrontiers in bioengineering and biotechnology · 2023Article
- Role of fourteen XRE-DUF397 pairs fromFrontiers in microbiology · 2023Article
- Marine Macrolides to Tackle Antimicrobial Resistance ofMarine drugs · 2022Review
- Genome plasticity as a paradigm of antibiotic resistance spread in ESKAPE pathogens.Environmental science and pollution research international · 2022Review
- A taxonomically representative strain collection to explore xenobiotic and secondary metabolism in bacteria.PloS one · 2022Article
- The Nonribosomal Peptide Valinomycin: From Discovery to Bioactivity and Biosynthesis.Microorganisms · 2021Review
- Genomics Characterization of an EngineeredFrontiers in bioengineering and biotechnology · 2021Article
- Draft Genome Sequences of Two Polycyclic Tetramate Macrolactam Producers,Microbiology resource announcements · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Due to the worldwide prevalence of multidrug-resistant pathogens and high incidence of diseases such as cancer, there is an urgent need for the discovery and development of new drugs. Nearly half of the FDA-approved drugs are derived from natural products that are produced by living organisms, mainly bacteria, fungi, and plants. Commercial development is often limited by the low yield of the desired compounds expressed by the native producers. In addition, recent advances in whole genome sequencing and bioinformatics have revealed an abundance of cryptic biosynthetic gene clusters within microbial genomes. Genetic manipulation of clusters in the native host is commonly used to awaken poorly expressed or silent gene clusters, however, the lack of feasible genetic manipulation systems in many strains often hinders our ability to engineer the native producers. The transfer of gene clusters into heterologous hosts for expression of partial or entire biosynthetic pathways is an approach that can be used to overcome this limitation. Heterologous expression also facilitates the chimeric fusion of different biosynthetic pathways, leading to the generation of "unnatural" natural products. The genus Streptomyces is especially known to be a prolific source of drugs/antibiotics, its members are often used as heterologous expression hosts. In this review, we summarize recent applications of Streptomyces species, S. coelicolor, S. lividans, S. albus, S. venezuelae and S. avermitilis, as heterologous expression systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.